Core Insights - Viridian Therapeutics, Inc. (NASDAQ:VRDN) is a biotechnology company focused on developing treatments for rare diseases, with RBC Capital setting a price target of $45, indicating a potential increase of about 63.64% from its current price of $27.50, reflecting strong confidence in the company's future performance [1][5] Financial Position - Viridian is positioned for profitability in 2026 due to successful financing transactions that have eliminated the need for further share dilution, which is a positive sign for investors [2][5] - The current stock price of VRDN is $27.50, showing a 12.61% increase or $3.08, with a market capitalization of approximately $2.23 billion and a trading volume of 4.86 million shares today [4] Competitive Landscape - The competitive landscape is shifting as Roche's Enspryng (satralizumab) has shown disappointing phase 3 results in treating thyroid eye disease, which reduces competitive pressure on Viridian's veligrotug and VRDN-003, potentially enhancing its market position and increasing market share in this therapeutic area [3][5]

Core Insights - Viridian Therapeutics, Inc. (NASDAQ:VRDN) has been upgraded to "Outperform" by RBC Capital, with a price target increase from $41 to $45, while the stock is currently priced at $27.45 [1][6] - The company is expected to have a promising year in 2026, having successfully completed financing transactions that will allow it to reach profitability without further share dilution [2][6] - Disappointing phase 3 results of Roche's Enspryng in treating thyroid eye disease have reduced competitive pressure on Viridian's treatments, veligrotug and VRDN-003, enhancing its market position [3][6] Financial Performance - VRDN's stock has seen a 12.41% increase, with a change of $3.03, and has fluctuated between $24.93 and $28.60 on the day of reporting [4] - The company's market capitalization is approximately $2.23 billion, with a trading volume of 3,957,014 shares, indicating strong investor interest [5]

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.Shares of Viridian Therapeutics, Inc. ( VRDN ) have advanced 29% since my last update in ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorp ...

Exhibit 99.1 Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress • $289 Million Public Equity Of ering in October 2025. On October 21, 2025, the company announced a public offering of common stock with gross proceeds of approximately $251.4 million, consisting of 11,425,000 shares sold at a public offering price of $22.00 per share. Following the announcement, the underwriters exercised their over-allotment option to purchase an additional 1,713,750 shares of co ...

Core Insights - Viridian Therapeutics, Inc. reported strong business performance with the successful submission of its Biologics License Application (BLA) for veligrotug [1] - The company completed enrollment in both pivotal clinical trials, indicating progress in its drug development pipeline [1] Financial Results - The financial results for the third quarter ended September 30, 2025, were highlighted, showcasing the company's ongoing commitment to developing treatments for serious and rare diseases [1]

Core Points - Viridian Therapeutics has successfully submitted a Biologics License Application (BLA) for its investigational therapy, veligrotug, to the U.S. FDA for the treatment of thyroid eye disease (TED) [1][2] - The BLA submission is supported by data from two pivotal phase 3 clinical trials, THRIVE and THRIVE-2, which met all primary and secondary endpoints [2][5] - Veligrotug has received Breakthrough Therapy Designation, which may support eligibility for Priority Review by the FDA [1][3] Company Overview - Viridian Therapeutics is a biotechnology company focused on developing potentially best-in-class medicines for serious and rare diseases [1][6] - The company is advancing multiple candidates for TED, including veligrotug and VRDN-003, with ongoing global phase 3 clinical trials [7] - Viridian's expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates [6][8] Clinical Development - Veligrotug is an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody in phase 3 development for TED [4] - The pivotal trials THRIVE and THRIVE-2 demonstrated a rapid onset of clinical benefit and statistically significant effects on multiple diplopia endpoints [5][7] - The BLA submission aims for a potential commercial launch of veligrotug in mid-2026, contingent on FDA approval [3]

Core Viewpoint - Viridian Therapeutics, Inc. has announced the pricing of an underwritten public offering of its common stock, indicating a strategic move to raise capital for its operations in the biotechnology sector [1] Company Summary - Viridian is offering a total of 11,425,000 shares of common stock at a public offering price of $22.00 per share, which reflects the company's efforts to secure funding for the development of medicines targeting serious and rare diseases [1] - The company has granted underwriters a 30-day option to purchase additional shares, which could further enhance the capital raised through this offering [1]

Group 1 - The article does not provide any specific content or key points related to a company or industry [1]

Core Insights - The individual has a B.Tech degree in Mechanical Engineering and nearly twenty-five years of experience in the oil and gas sector, primarily in the Middle East [1] - The investment strategy is informed by traits of efficiency, carefulness, and discipline, developed through extensive industry experience [1] - There is a sustained interest in U.S. equity markets, focusing on technology, energy, and healthcare sectors [1] - The investment approach has evolved from growth investing to a blend of value and growth, emphasizing the understanding of business economics and competitive advantages [1] - The individual believes in the importance of allowing time and compounding to enhance investment returns, particularly in high-quality businesses [1] - A moderately conservative orientation is adopted, with a focus on minimizing downside risk as retirement approaches [1] - Recent rebalancing towards income-generating assets such as dividend-paying equities and REITs reflects a shift in investment priorities [1] - Investing is viewed as a means to achieve peace of mind, not just high returns [1] - The individual aims to engage with a community of investors interested in the intersection of business fundamentals and intelligent investing [1] - There is a commitment to investing in ecologically sensitive businesses, as represented by the chosen icon [1]